Abstract | BACKGROUND: METHODS AND RESULTS: The study population consisted of 80 patients with lung adenocarcinoma, 40 patients with ovarian adenocarcinoma and 80 healthy subjects. Serum FST levels in patients and healthy subjects were measured using ELISA. The results showed that the positive ratio of serum FST levels was 51.3% (41/80), which was comparable to the sensitivity of FST in 40 patients with ovarian adenocarcinoma (60%, 24/40) using the 95th confidence interval for the healthy subject group as the cut-off value. FST expressions in lung adenocarcinoma were examined by immunohistochemical staining, we found that lung adenocarcinoma could produce FST and there was positive correlation between the level of FST expression and the differential degree of lung adenocarcinoma. Furthermore, the results showed that primary cultured lung adenocarcinoma cells could secrete FST, while cells derived from non- tumor lung tissues almost did not produce FST. In addition, the results of CCK8 assay and flow cytometry showed that using anti-FST monoclonal antibody to neutralize endogenous FST significantly augmented activin A-induced lung adenocarcinoma cells apoptosis. CONCLUSIONS:
|
Authors | Fangfang Chen, Ping Ren, Ye Feng, Haiyan Liu, Yang Sun, Zhonghui Liu, Jingyan Ge, Xueling Cui |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 10
Pg. e111398
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25347573
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Follistatin
|
Topics |
- Adenocarcinoma
(blood)
- Adult
- Aged
- Biomarkers, Tumor
(blood)
- Case-Control Studies
- Female
- Follistatin
(blood)
- Humans
- Lung Neoplasms
(blood)
- Male
- Middle Aged
|